By Melodie Holden - Director of Operations, Venture Strategies
An old drug will gain a new use in Nigeria this week when misoprostol will be distributed for prevention and control of post-partum hemorrhage, the life-threatening bleeding after childbirth that commonly occurs in developing countries.
Our non-profit organization, Venture Strategies for Health and Development, worked with UC Berkeley's School of Public Health to help Nigerian colleagues obtain the world's first regulatory approval of misoprostol for controlling postpartum hemorrhage, the leading cause of maternal death.
UC Berkeley issued a press release which was picked up by several news agencies. Please visit our web site to read the full story (link below).
We have obtained the lowest prices in the world from high quality manufacturers in China and Egypt and are helping to facilitate the type of South-South trade established in Nigeria with other countries in Africa and the Middle East, at their request.
If you would like to read more about our misoprostol projects and related publications, we invite you to see our web site (link below).
Project Reports on GlobalGiving are posted directly to globalgiving.org by Project Leaders as they are completed, generally every 3-4 months. To protect the integrity of these documents, GlobalGiving does not alter them; therefore you may find some language or formatting issues.
If you donate to this project or have donated to this project, you will get an e-mail when this project posts a report. You can also subscribe for reports via e-mail without donating or by subscribing to this project's RSS feed.
Get Reports via Email
We'll only email you new reports and updates about this project.
Project Leader: Allison Boiles
Thanks to 209 donors like you, a total of $33,480 was raised for this project on GlobalGiving.
Combined with other sources of funding, this project raised enough money to fund the outlined activities and is no longer accepting donations.
Still want to help?
Find another project in
that needs your help.